PsychRounds: The Psychiatry Podcast

Apologies for our little hiatus - a couple of us had cross-country moves in June. But we're back! Today we have an episode on the rising use of recreational Kratom and pertinent tidbits to know from a psychiatry standpoint.

References:

https://pmc.ncbi.nlm.nih.gov/articles/PMC8924421/

https://www.ncbi.nlm.nih.gov/books/NBK585120/

https://pmc.ncbi.nlm.nih.gov/articles/PMC10846393/

https://pmc.ncbi.nlm.nih.gov/articles/PMC10177737/

Welcome back! Today, we are looking at Modafinil and it's nuanced use in psychiatry.

References:
Provigil (modafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfdadocs/label/2015/020717s037s038lbl.pdf

Schwartz JR. Modafinil in the treatment of excessive sleepiness. Drug Des Devel Ther. 2009;2:71–85.

Kaplan S, Goehring EL Jr, Engel T, et al. Cardiovascular outcomes associated with modafinil in patients with obstructive sleep apnea. Pharmacoepidemiol Drug Saf. 2018;27(11):1182–1190. doi:10.1002/pds.4642

Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738. doi:10.1016/S2215-0366(18)30269-4

Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101–1107. doi:10.4088/JCP.13r08560

Bahji A, Mesbah-Oskui L. Comparative efficacy and safety of stimulant-type medications for depression: a systematic review and network meta-analysis. J Affect Disord. 2021;292:416–423. doi:10.1016/j.jad.2021.05.119

Nunez NA, Singh B, Jorgensen A, et al. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials. Bipolar Disord. 2020;22(2):109–120. doi:10.1111/bdi.12859

Welcome Back! Today we are discussing the medication Naltrexone and its uses in psychiatry.

References:
https://www.ncbi.nlm.nih.gov/books/NBK534811/

https://pubmed.ncbi.nlm.nih.gov/24825644/

https://pubmed.ncbi.nlm.nih.gov/26798982/

https://www.nejm.org/doi/full/10.1056/NEJMct0801733

https://pubmed.ncbi.nlm.nih.gov/26798982/

Welcome back! Today, we will be discussing the placebo effect.

References:
https://pubmed.ncbi.nlm.nih.gov/16503356/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003660/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556377/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714297/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694178/
https://www.psychiatrypodcast.com/psychiatry-psychotherapy-podcast/2018/11/19/understanding-placebo

Welcome back! Today we are talking all about Amantadine, and it's uses in psychiatry.